• Je něco špatně v tomto záznamu ?

Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury

MM. Ullrich, B. Pulipaka, J. Yin, J. Hlinková, F. Zhang, MW. Chan, FJ. O'Brien, A. Dervan, K. Dziemidowicz

. 2025 ; 22 (6) : 2905-2916. [pub] 20250516

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015391

Spinal cord injury (SCI) results in paralysis, driven partly by widespread glutamate-induced secondary excitotoxic neuronal cell death in and around the injury site. While there is no curative treatment, the standard of care often requires interventive decompression surgery and repair of the damaged dura mater close to the injury locus using dural substitutes. Such intervention provides an opportunity for early and local delivery of therapeutics directly to the injured cord via a drug-loaded synthetic dural substitute for localized pharmacological therapy. Riluzole, a glutamate-release inhibitor, has shown neuroprotective potential in patients with traumatic SCI, and therefore, this study aimed to develop an electrospun riluzole-loaded synthetic dural substitute patch suitable for the treatment of glutamate-induced injury in neurons. A glutamate-induced excitotoxicity was optimized in SH-SY5Y cells by exploring the effect of glutamate concentration and exposure duration. The most effective timing for administering riluzole was found to be at the onset of glutamate release as this helped to limit extended periods of glutamate-induced excitotoxic cell death. Riluzole-loaded patches were prepared by using blend electrospinning. Physicochemical characterization of the patches showed the successful encapsulation of riluzole within polycaprolactone fibers. A drug release study showed an initial burst release of riluzole within the first 24 h, followed by a sustained release of the drug over 52 days to up to approximately 400 μg released for the highest loading of riluzole within fiber patches. Finally, riluzole eluted from electrospun fibers remained pharmacologically active and was capable of counteracting glutamate-induced excitotoxicity in SH-SY5Y cells, suggesting the clinical potential of riluzole-loaded dural substitutes in counteracting the effects of secondary injury in the injured spinal cord.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015391
003      
CZ-PrNML
005      
20250731090941.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.molpharmaceut.4c01270 $2 doi
035    __
$a (PubMed)40378306
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ullrich, Mathilde M $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K
245    10
$a Neuroprotective Riluzole-Releasing Electrospun Implants for Spinal Cord Injury / $c MM. Ullrich, B. Pulipaka, J. Yin, J. Hlinková, F. Zhang, MW. Chan, FJ. O'Brien, A. Dervan, K. Dziemidowicz
520    9_
$a Spinal cord injury (SCI) results in paralysis, driven partly by widespread glutamate-induced secondary excitotoxic neuronal cell death in and around the injury site. While there is no curative treatment, the standard of care often requires interventive decompression surgery and repair of the damaged dura mater close to the injury locus using dural substitutes. Such intervention provides an opportunity for early and local delivery of therapeutics directly to the injured cord via a drug-loaded synthetic dural substitute for localized pharmacological therapy. Riluzole, a glutamate-release inhibitor, has shown neuroprotective potential in patients with traumatic SCI, and therefore, this study aimed to develop an electrospun riluzole-loaded synthetic dural substitute patch suitable for the treatment of glutamate-induced injury in neurons. A glutamate-induced excitotoxicity was optimized in SH-SY5Y cells by exploring the effect of glutamate concentration and exposure duration. The most effective timing for administering riluzole was found to be at the onset of glutamate release as this helped to limit extended periods of glutamate-induced excitotoxic cell death. Riluzole-loaded patches were prepared by using blend electrospinning. Physicochemical characterization of the patches showed the successful encapsulation of riluzole within polycaprolactone fibers. A drug release study showed an initial burst release of riluzole within the first 24 h, followed by a sustained release of the drug over 52 days to up to approximately 400 μg released for the highest loading of riluzole within fiber patches. Finally, riluzole eluted from electrospun fibers remained pharmacologically active and was capable of counteracting glutamate-induced excitotoxicity in SH-SY5Y cells, suggesting the clinical potential of riluzole-loaded dural substitutes in counteracting the effects of secondary injury in the injured spinal cord.
650    12
$a riluzol $x aplikace a dávkování $x chemie $x farmakologie $7 D019782
650    12
$a poranění míchy $x farmakoterapie $7 D013119
650    12
$a neuroprotektivní látky $x aplikace a dávkování $x chemie $x farmakologie $7 D018696
650    _2
$a lidé $7 D006801
650    _2
$a kyselina glutamová $x metabolismus $7 D018698
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a neurony $x účinky léků $7 D009474
650    _2
$a zvířata $7 D000818
650    _2
$a uvolňování léčiv $7 D065546
650    _2
$a implantované léky $7 D004343
650    _2
$a polyestery $x chemie $7 D011091
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pulipaka, Bhavana $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland
700    1_
$a Yin, Jing $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K
700    1_
$a Hlinková, Jana $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K $u Department of Tissue Engineering, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 142 20, Czechia $u Department of Biomaterials, Faculty of Dentistry, University of Oslo, Geitmyrsveien 69/71, PB 1142 Blindern, Oslo 0317, Norway
700    1_
$a Zhang, Fangyuan $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K
700    1_
$a Chan, Michael W $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K $1 https://orcid.org/0009000071761809
700    1_
$a O'Brien, Fergal J $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland $u Advanced Materials and Bioengineering Research Centre (AMBER), Trinity College Dublin, College Green, Dublin 2 D02 W9K7, Ireland
700    1_
$a Dervan, Adrian $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), 123 St Stephens Green, Dublin 2 D02 YN77, Ireland $u Advanced Materials and Bioengineering Research Centre (AMBER), Trinity College Dublin, College Green, Dublin 2 D02 W9K7, Ireland
700    1_
$a Dziemidowicz, Karolina $u Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, U.K $1 https://orcid.org/0000000155015646
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 22, č. 6 (2025), s. 2905-2916
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40378306 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090936 $b ABA008
999    __
$a ok $b bmc $g 2366308 $s 1252516
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 22 $c 6 $d 2905-2916 $e 20250516 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...